Kala Bio Inc. has entered into a new Convertible Loan Agreement with an individual investor, under which the company will receive up to $375,000 in funding. The agreement stipulates that $187,500 will be provided by November 10, 2025, with the remaining $187,500 due by November 12, 2025, unless extended by mutual agreement. The proceeds are restricted to facilitating negotiations and finalizing an additional investment transaction with the lender, as well as preparing and filing the company's upcoming Quarterly Report. During this period, Kala Bio has agreed not to seek alternative investment offers. The loan may be converted into shares of common stock, and the securities issued under this agreement will be exempt from SEC registration under Regulation S, as the lender is a non-U.S. person. The company cautioned that failure to secure further financing could lead to the resumption of foreclosure efforts by Oxford on its assets.